T umors may co-opt the programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) immune checkpoint pathway to avoid host immune surveillance. Therapeutic blockade of this pathway unleashes the host immune response, often leading to durable tumor regressions in patients with advanced cancers. 1 Monoclonal antibodies targeting PD-1 or PD-L1
have been approved by the US Food and Drug Administration to treat melanoma, non-small-cell lung carcinoma (NSCLC), Hodgkin lymphoma, and carcinomas of the kidney, urothelial tract, and squamous cell carcinoma of the head and neck (SCCHN).
Immunosuppressed patients with cancer, including those with HIV, have historically been excluded from immunotherapy trials and it is unknown if immune checkpoint pathways are active in the tumors of these patients. However, many HIV-associated cancers are linked to oncogenic viruses, such as human papillomavirus (HPV) in anal squamous cell carcinoma (SCC). 2 In immunocompetent patients, virus-associated cancers contain immune-active microenvironments and some have responded well to anti-PD-1 therapies. 3, 4 In patients with HIV, the presence of strong viral antigens in the tumor immune microenvironment (TME) could potentially offset the effects of HIV-associated systemic immune dysfunction. The current study compared the TME in HIV-positive vs HIV-negative patients with anal SCC, a virus-associated cancer that has not previously been characterized for PD-1/PD-L1 expression and where new treatment options would be of great value.
Methods
Forty-eight anal SCC specimens were identified from 29 HIV-positive and 19 HIV-negative patients; 8 specimens were excluded for not meeting pathologic criteria (eMethods in the Supplement). Tumor tissue microarrays (TMAs) using central tumor cores were stained with immunohistochemistry (IHC) for immune checkpoint molecules (PD-1, PD-L1, LAG-3) and immune cell (IC) subsets (CD3, CD4, CD8, CD68). Membranous (cell surface) PD-L1 expression on tumor or infiltrating ICs, intensity of IC infiltration, and patterns of PD-L1 expression associated with IC infiltrates were scored as previously described. 5 Immune cell subsets were quantified using HALO image analysis (Indica Laboratories). Tumor cells from areas of adaptive PD-L1 expression adjacent to ICs were captured by laser capture microdissection and used to compare gene expression profiles between tumors from HIV-positive and HIV-negative patients. Analyses were blinded to patient HIV status. Statistical significance was determined with a 2-sided α level of .05 unless otherwise stated. Full methods are provided in the Supplement. All specimens were collected in compliance with the institutional review boards of the AIDS and Cancer Specimen Resource and Johns Hopkins Hospital; all patients had signed consent or waiver of consent forms for tissue use.
Results
Forty anal SCCs from 23 HIV-positive and 17 HIV-negative unique patients were studied (eTable 1 in the Supplement). Peripheral blood CD4 counts were available for 19 HIVpositive patients, with 10 (53%) below 200 cells/mm 3 (range,
60-597 cells/mm 3
). Nearly half (49%) of 35 patients with treatment data had received chemotherapy and/or radiation prior to specimen procurement. Details regarding treatment effect on immune parameters are provided in the eMethods and eResults in the Supplement.
Immune cell densities were similar between the 2 groups for all cellular subsets analyzed ( Table 1 ) (eFigure 1 in the Supplement), although there was a trend toward decreased CD4 to CD8 ratio in HIV-associated anal SCC. Peripheral CD4 counts were not associated with the density of any intratumoral IC subset or checkpoint expression (eTable 2 in the Supplement). Varied patterns of tumor cell PD-L1 expression, including adaptive, constitutive, and mixed, 1, 5 were observed in tumors from both HIV-positive and HIV-negative patients ( Figure 1 ). When all 40 cases were assessed, IC PD-L1 expression was correlated with the degree of IC infiltration (r = 0.52; 95% CI, 0.26-0.78; P < .001) ( Table 2 ) and with intratumoral CD8 + T-cell density (r = 0.35; 95% CI, 0.11-0.59; P = .03) (eFigure 2 in the Supplement). In contrast, tumor cell PD-L1 expression was not significantly correlated with the degree of IC infiltration or intratumoral CD8 + T-cell density.
No significant differences were observed in tumor cell PD-L1 expression, adaptive PD-L1 expression, or presence of moderate to severe IC infiltrates in anal SCC from HIVpositive vs HIV-negative patients, although there was a trend toward increased IC PD-L1 expression in HIV-associated tumors (eFigure 3 in the Supplement). Although tobacco use was common among patients with anal SCC, smoking history was not associated with expression of the studied parameters. Whereas immune-related gene expression (including IFNG) in tumors from HIV-positive and HIV-negative patients was generally similar (Figure 2 ) (eTable 3 and eTable 4 in the Supplement), interleukin-18 (IL-18) expression was significantly elevated in the HIV-positive group.
Key Points
Question Does the tumor immune microenvironment differ between HIV-positive and HIV-negative patients with anal squamous cell carcinoma (SCC)?
Findings In this study of 40 tumor specimens from patients with anal SCC, there were no significant differences in programmed death-ligand 1 (PD-L1) expression or programmed cell death protein 1 (PD-1), CD3, CD4, CD8, CD68, or LAG-3 immune cell subsets by immunohistochemical analysis. Immune-related gene expression profiles were also similar between HIV-positive and HIV-negative patients.
Meaning HIV status alone does not affect the degree of immune cell infiltration or checkpoint molecule expression in tumors from patients with anal SCC, supporting the ongoing clinical investigation of anti-PD-1 and PD-L1 therapies in this population. anal SCC may be a particularly good candidate for anti-PD-1 and anti-PD-L1 immunotherapy. T cells expressing PD-1, LAG-3, and Tim3 have been described in anal SCC. 13 The expression of LAG-3 was also observed in this study by IHC, supporting a potential second therapeutic immune checkpoint target in this cancer type.
Encoding an inflammatory cytokine, IL18 was the most highly upregulated gene in HIV-associated anal SCCs. Interleukin 18 (IL-18) is increased in the blood of patients with HIV, 14 and the dysregulated cytokine milieu that characterizes late-stage HIV infection is thought to alter the balance of IL-18 activity to favor HIV replication and disease progression. 15 In this study, elevated levels of IL18 thus may reflect advanced HIV infection, consistent with very low peripheral CD4 counts in 2 of the 3 patients studied (60 and 67 cells/mm 3 ).
Limitations
This study has several limitations. Almost half of the patients were pretreated and 31% of the specimens were from recurrent tumors, and thus our findings may not be generalizable to all patients with anal SCC. In addition, assessment of central cores from TMAs may underestimate immune activity at the tumor-stromal interface or in draining lymph nodes. The limited number of specimens might also have affected our ability to detect small differences in IC subsets, checkpoint molecules, and immune-related gene expression between HIV-positive and HIV-negative patients, or between patients with CD4 counts above and below 200 cells/mm 3 . However, for the 2 HIV-positive patients with very low CD4 counts, we did not identify a commensurate decrease in intratumoral CD4 density, and IFNG expression in these tumors appeared comparable to expression levels in tumors from HIV-negative patients.
Conclusions
This study suggests a similar degree of IC infiltration and expression of the clinically targetable immune checkpoints PD-L1 and PD-1 in anal SCCs from HIV-positive and HIVnegative patients. To our knowledge, this is the first study of its kind in anal SCC, a relatively rare tumor for which new treatment options are needed. Our findings, as well as early clinical data, 13 support ongoing clinical investigations of anti-PD-1, alone or in combination with anti-CTLA-4, in HIV-positive patients (NCT02314169 and NCT02408861). Furthermore, our findings provide a rationale for targeting LAG-3 in patients with advanced anal SCC. 
IFNG
The orange dots represent genes that are upregulated in specimens from HIV-positive compared with HIV-negative patients. The HIV-positive group overexpressed some cytokines or cytokine receptors (IL1A, IL17RC, IL10RB) and some markers related to T-cell activation (ICOSLG, P2RX1), and marginally overexpressed LAG3. Interleukin 18, a proinflammatory cytokine previously reported to be present at elevated levels in sera from HIV-positive individuals, was the most significantly overexpressed gene in the HIV-associated tumors (fold-change, 12.69, P < .001). IFNG, an inflammatory cytokine associated with adaptive PD-L1 expression, was expressed equivalently between the 2 groups. The horizontal dotted line indicates P = .05 and vertical dotted lines indicate 2.0-fold difference in expression levels. Data are normalized to PTPRC (CD45, pan immune cell marker). There was no significant difference in PTPRC expression among the samples. SCC indicates squamous cell carcinoma. 
eMethods and Results

Case selection
Tissue microarray (TMA) design
All tumor specimens were studied in a TMA format, which was exclusively available through the ACSR. The ACSR TMA was constructed using 1-2 core needle specimens (1 mm diameter) taken from the central aspect of each paraffin-embedded tumor. The JHH TMA was constructed using up to six cores (1 mm diameter) per tumor, with up to three cores each from the central or peripheral aspects.
Immunohistochemistry
IHC for CD3, CD4, CD8, and CD68 was performed according to standard automated methods.
IHC for PD-1 was performed as previously described. 2 IHC for PD-L1 was performed with the anti-PD-L1 monoclonal antibody SP142 (Spring Bioscience) at a concentration of 0.096 µg/mL, and antigen retrieval was performed in a citrate buffer, pH 6.0. A biotinylated anti-rabbit IgG (Becton-Dickinson) was used as a secondary antibody. Signal was developed using the ABC kit (Vector Elite PK-6100) followed by amplification with the Perkin Elmer tyramide signal amplification plus biotin kit (dilution 1:50). IHC for LAG-3, an immune checkpoint expressed on activated T cells, 3 was performed with the anti-LAG-3 monoclonal antibody 17B4 (LifeSpan BioSciences) at a concentration of 0.1 µg/mL following an antigen retrieval in citrate buffer, pH 6.0. Biotinylated anti-mouse IgG1 (Becton-Dickinson) was used as a secondary antibody at a concentration of 1.0 µg/mL. Signal was developed using the ABC kit (Vector PK-6100). Amplification was performed using the CSA kit (Dako K1500), and signal was visualized using streptavidin-HRP from the LSAB kit (Dako K0675) and DAB (Sigma D4293). Cases in this study had a minimum of one central core tumor specimen deemed adequate for pathologic analysis with three stains:
hematoxylin and eosin (H&E), anti-CD3, and anti-PD-L1.
Scoring of IC subsets and immune checkpoint expression
Membranous (cell surface) PD-L1 expression on tumor or infiltrating ICs was scored as previously described, 4 at approximately 0, 5%, 10%, and increasing 10% intervals. Cores with >5% expression on tumor cells or ICs were considered PD-L1+ for that cell type. For tumors with multiple cores, the tumor was considered positive for PD-L1 expression if at least 50% of the cores were positive.
Geographic association of PD-L1 expression and IC infiltrates was described according to the following patterns: constitutive (PD-L1 expression without IC infiltrates), adaptive (PD-L1 only in areas of IC infiltration), or mixed (broad areas of PD-L1 expression independent of ICs, but accentuated in areas of IC infiltration) (Fig. 1A-C) . 4, 5 Intensity of IC infiltrates was graded as none (0), mild (1, rare lymphocytes), moderate (2, peripheral infiltration of tumor or extending away from perivascular regions), or severe (3, diffuse infiltration or dense infiltrate surrounding the complete tumor perimeter). For tumors with multiple cores, an average IC infiltration score was generated.
Computerized image analysis and quantification of IC infiltrates
Immunostained TMA slides were scanned at 20x (0.49 micrometers per pixel) using the Aperio Scanscope (Leica Biosystems). Individual 1 mm tissue cores were considered adequate based on the following criteria: (1) at least 25% tissue was intact on core cross section, (2) at least 10% of tissue was composed of tumor cells, and (3) IHC staining was compatible with digital scoring (e.g. tinctorial quality of slide amenable to algorithmic assessment). HALO (Indica Labs) was used to annotate each core image to exclude necrotic, folded, and fragmented areas. IC densities were quantified with the HALO Immune Cell Module using best-fit parameters for: CD3, CD4, CD8, CD68, PD-1, and LAG-3 (eFigure 4). For cases with multiple cores, a mean IC density was used.
Comparison of tissue microarray (TMA) central cores vs. whole mount anal SCC specimens
To 
Laser capture microdissection (LCM) and quantitative (q)RT-PCR
Seven whole mount tumor specimens, from 3 HIV(+) and 4 HIV(-) patients, were cut into 7-µM sections on Arcturus PEN membrane glass slides (Applied Biosystems). LCM was performed with a Leica LMD6000 Laser Capture Microdissection microscope to capture areas of adaptive tumor cell PD-L1 expression associated with PD-L1+ ICs. Total RNA was isolated using previously reported methods. 4, 6, 7 Taqman low-density array cards were used for multiplex qRT-PCR amplification of 61 immune-related genes and 3 control genes (18S, GUSB, and PTPRC), according to the manufacturer's protocol (eTable 3). The comparative Ct method (2-Ct) was used to calculate gene expression fold-changes in specimens from HIV(+) vs. HIV(-) patients.
Statistical analysis
Wilcoxon rank-sum tests were used to assess differences in IC subset densities between tumors from HIV(+) and HIV(-) patients. The correlation between PD-L1 expression and level of IC infiltration within a tumor core was estimated with Pearson's correlation test. Chi-squared tests were used to assess differences in proportion of tumors with PD-L1 expression and moderate-severe levels of infiltrating ICs between HIV(+) and HIV(-) patients. Among HIV(+) patients with peripheral blood CD4 T cell count values available, Wilcoxon rank-sum tests were used to assess differences in IC subset densities between tumors from patients with peripheral blood CD4 T cell counts below or above 200 cells/mm 3 , and
Pearson's correlation tests were used to estimate the correlation between CD4 counts and IC densities.
qRT-PCR data were analyzed using the Welch t-test. Statistical analyses were performed using SAS (version 9.4; SAS Institute Inc).
Effect of prior treatment and tumor recurrence on PD-L1 expression and IC infiltrates
We compared PD-L1 expression and IC infiltrates for 35 patients with available clinical treatment data. Nearly half (49%) had received chemotherapy and/or radiation approximately 0.5-24 months prior to specimen procurement. Histopathologic review did not reveal features of radiation dermatitis/mucositis or active chemotherapy effect in any specimen. We found that CD4+ T cells were significantly decreased in tumors from patients who had received prior treatment (median 122 vs. 167 cells/mm 2 , respectively, P=0.026), but no significant differences were observed in any other immune parameters studied. Overall, there may be some impact arising from chemotherapy and/or radiation treatment prior to specimen procurement, but these results must be interpreted with caution due to our small sample size and the limited availability of clinical information in some cases. Additionally, 11 of 35 specimens (31%) with available information were from patients with recurrent disease. A significantly higher proportion of recurrent tumors expressed PD-L1 as compared to non-recurrent tumors (82% vs. 33%, respectively, P=0.008), but there were no significant differences observed in any other immune parameter. 
